Navamedic ASA

As of June 30, 2025, Navamedic ASA carries a market capitalization of 388.58M, placing it among publicly traded companies globally. Its enterprise value stands at 475.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Navamedic ASA's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2025, Navamedic ASA has 17.96M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 0.69, and the price-to-book ratio stands at 1.79.

As of June 30, 2025, Navamedic ASA trades at an EV/EBITDA multiple of 10.62 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.85 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.90 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 475.51M versus a market cap of 388.58M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Navamedic ASA maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.55, indicating elevated leverage, while an interest coverage ratio of 5.03 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Navamedic ASA posted a negative return on equity (ROE) of -5.94, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.55, reflecting losses generated across the asset base. The company generates approximately 13.10M in revenue per employee across its workforce of 42.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.53 indicates how many times Navamedic ASA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Navamedic ASA recorded 8.21M in income tax expense. The company reported a pretax loss of -1.46M and -9.67M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Navamedic ASA's stock has declined approximately 41.59% over the past 52 weeks.

Over the twelve months ended June 30, 2025, Navamedic ASA generated 556.80M in revenue and converted that into -9.67M in net income, yielding earnings per share of -0.54. EBITDA reached 44.76M, while operating income came in at 37.57M.

As of June 30, 2025, Navamedic ASA holds 46.36M in cash and equivalents against 133.28M in total debt, resulting in a net debt position of 87.69M. Total book value stands at 216.55M, with working capital of 50.72M providing operational flexibility.

Navamedic ASA produced 32.15M in operating cash flow over the twelve months ended June 30, 2025. After subtracting -773,000.00 in capital expenditures, free cash flow totaled 31.38M - equivalent to 1.77 per share.

Over the twelve months ended June 30, 2025, Navamedic ASA posted a gross margin of 39.75, reflecting its pricing power and cost economics. The operating margin of 6.75 and net profit margin of -1.74 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield stands at 8.14, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt.

Navamedic ASA's most recent stock split took place on July 18, 2025 with a 473:481 split ratio.

As of June 30, 2025, Navamedic ASA has an Altman Z-Score of 4.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.